Celestra Inc. (KOSDAQ:352770)
5,250.00
-1,365.00 (-20.63%)
At close: Apr 3, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Bio | 7.08B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Food and Food Service | 4.19B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Investment | 935.84K |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 143.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - Others | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - Others Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - Others | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - Others Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - GenoSolution | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - GenoSolution Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - AmoyDx ROS | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - AmoyDx ROS Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - AmoyDx ROS | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - AmoyDx ROS Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - BioComputer | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Service - BioComputer Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - BioServer | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - BioServer Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufactured - CD-PRIME | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Manufactured - CD-PRIME Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Geno Cafe, Etc. | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Geno Cafe, Etc. Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Merchandised - COVID-19 | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Genetic Testing | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Molecular Genetic Testing Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| South Korea | 11.41B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South Korea Growth | -50.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|